Genmab

Genmab has been awarded Finansforeningen’s Special Prize 2025, selected unanimously by the Accounting Committee for our open, timely, and consistent investor communication. Finansforeningen (CFA Society Denmark) is a Danish professional association for finance and investment professionals. Thank you to our investors and stakeholders for the continued trust, and to our teams who work with the goal of making a difference for patients through antibody medicines. Learn more: cfa.dk. #InvestorRelations

#InvestorUpdate: Today, Genmab held its 2026 Annual General Meeting. Our CEO Jan van de Winkel and CFO Anthony Pagano presented Genmab’s 2025 Annual Report. For more information, visit: lnkd.in/etUANWXZ.

"I believe breakthrough science can be a miracle for a patient and her family.” - Robin Cohen Tune in to this edition of #AntibodyHour 🕙 to hear from Robin Cohen, BSN, CEO of the Sandy Rollman Ovarian Cancer Foundation, as she shares how a patient’s final words shaped her mission. Robin reminds us that “a win” looks different for every patient. Some ask, “How long will I live?” Others ask, “How will I live?” Those questions challenge all of us as scientists, clinicians, and colleagues to focus on what truly matters to each individual patient and their family. At Genmab, stories like these are grounding. They remind us why breakthrough science and urgency matter, and why every antibody we work on carries our aspiration to transform the lives of patients. #PatientFirst

In honor of International Women’s Day, we were pleased to welcome Courtney Clark for a special keynote on building resilience and navigating change, through what she refers to as revisionary thinking. The session includes reflection facilitated by Amy Whited and Leslie Amendola. Genmab is also making a donation to @WomanspaceInc, a secure space for women, as part of our commitment to making a positive impact in the communities where we live and work. #CommunityatGenmab #InternationalWomensDay

During this episode of #AntibodyHour 🕙, Patient Advisor Linda Emery reflects on her personal experience with cancer and the moments that defined it. She shares that while she never felt misunderstood during treatment, she found purpose by turning her experience into action and continues to find meaning in helping others. Thank you, Linda, for sharing your story. We’re grateful for your perspective as we continue working to bring innovative antibody medicines to patients. #PatientFirst

We’re at @ESGO_society 2026, joining experts shaping the future of gynecologic oncology. Our work in antibody science starts with patients and is strengthened by connection across the scientific community. Visit booth #4 and bit.ly/3ZES0sy. #GynecologicOncology

#InvestorUpdate: Genmab has published its 2025 Annual Report. We have evolved into a fully integrated biotech with a wholly owned, diversified pipeline. Our focus remains unchanged: translating our antibody science into meaningful outcomes for patients. Learn more: lnkd.in/e4DdAstZ.

#ICYMI: Our 2025 Annual Report is now live. We highlight how strategic investments and progress across our late-stage pipeline are advancing our evolution into a fully integrated biotech — focused on delivering meaningful innovation for patients and sustainable growth. Visit: genmab.com/news-insights/….

On #InternationalDayOfWomenAndGirlsInScience, we spotlight our inspiring colleagues who are dedicated to overcoming challenges, advancing science, and turning complexity into progress for patients. Tune in to this week’s #AntibodyHour 🕙 to hear from our team as they share how our can-do, proactive mindset keeps Genmab innovative, with the goal of impacting patients. #Innovation #WomeninSTEM #WomeninScience

Congratulations to Genmab CEO Jan van de Winkel, Ph.D., on receiving the @BioNJ 2026 Dr. Sol J. Barer Award for Vision, Innovation and Leadership. This honor recognizes his patient-first leadership, commitment to breakthrough antibody science, and lasting impact on the biotech and pharma community in New Jersey and beyond. Under Jan’s leadership, Genmab continues to evolve into an integrated biotech with a clear purpose to improve patients’ lives. #Biotech #Leadership #Genmab #BioNJ

On this #WorldCancerDay, we are spotlighting a powerful conversation between Patient Advisor Jennifer Thompson, and EVP, CPO, Christopher Cozic. Follow along with us as we bring back our #AntibodyHour🕙 series highlighting our people and purpose as we aspire to impact patient lives with innovative antibody medicines. #InspiredByPatients #Innovation

This #WorldCancerDay, we’re united by what makes each cancer journey unique. Our colleague Iris’ words remind us why it is vital to put patients at the center of innovation at Genmab. Learn how we aspire to empower patients and care partners: genmab.com/patients-care-…. #UnitedByUnique

Growing Together for a Greener Future! Our colleagues teamed up with Trees for All to plant trees in the beautiful Het Groene Woud, another meaningful step in our ongoing commitment to sustainability and positive impact. #Sustainability #CSR

This week, Genmab hosted a Career Exploration Day at our Utrecht site, welcoming nearly 80 students. Students listened in to several scientific presentations, worked on a data analysis assignment, and took a tour of the site, giving future scientists a firsthand look at what a career in biotech looks like. #STEM #CareerExploration

#InvestorUpdate for Genmab Shareholders: Stay informed by registering your email to receive electronic shareholder communications from Genmab, including notices for our Annual General Meetings. Simply log in to the Investor Portal and add your email under “My Profile.” Click here: investor.vp.dk/ip/ctrl/portal….

#ICYMI: President & CEO Jan van de Winkel shared an update on our transformation into a fully integrated biotech with a growing portfolio of proprietary medicines and a promising late-stage pipeline at #JPM2026, hosted by @jpmorgan. Watch the replay here: ir.genmab.com/events-present….

As Genmab presents at #JPM2026, we’re continuing to build the foundation of a more scalable, digitally enabled R&D engine to advance the company’s vision of bringing transformative antibody-based medicines to patients. Read more: gmab.ly/J6kq50XSV0P.

#NewsUpdate: Genmab has partnered with @Anthropic to accelerate research and development processes through agentic artificial intelligence. @claudeai Read more: gmab.ly/J6kq50XSV0P.

Happy New Year from Genmab! As we enter 2026, our purpose to improve patients’ lives through innovative antibody therapeutics continues to inspire us. We’ll be presenting at the 44th @jpmorgan Healthcare Conference. Read more: gmab.ly/MyRA50XSbXE. #JPM2026

As 2025 ends, we’re reflecting on a year of scientific progress toward our vision: improving the lives of patients with innovative antibody medicines. Thank you to the patients, caregivers, partners & colleagues who inspire us. Follow along on our journey as we enter 2026: bit.ly/3Vp0YaO. #InspiredByPatients #PatientsFirst